Loading
A phase 3 trial of L19IL2 + L19TNF in melanoma, run by Philogen S.p.A., active and no longer recruiting.
Neoadjuvant L19IL2/L19TNF- Pivotal Study is a phase 3 interventional study registered as NCT02938299 by Philogen S.p.A., with 214 participants enrolled, started 2016-07-01 and due to reach its primary completion in 2024-10. Interventions recorded: L19IL2 + L19TNF and Surgery.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
A second publication from the Neoadjuvant L19IL2 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT02938299 with the most citations, so it is the natural first reading for anyone following the Neoadjuvant L19IL2 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares Philogen S.p.A., Stage III melanoma (after surgery), Melanoma and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Stage III melanoma (after surgery), Melanoma and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/